Preventing Cancer: The ROOT Protocols
By Paul Marik, MD and Justus Hope, MD
Introduction
Cancer is a global threat, responsible for more than 10 million deaths annually. In the United States, cancer is the second most common cause of death, exceeded only by heart disease. The American Cancer Society estimated that 2 001 140 new cancer cases and 611 720 cancer-related deaths were projected to occur in the United States in 2024. (1) A recent study highlights a troubling trend: 17 types of cancer are becoming more prevalent in younger generations, with associated mortality also rising. (2) Colorectal cancer, once the fourth most common cause of cancer death among both men and women under 50 in the late 1990s, is now the leading cause in men and the second leading cause in women. (1)
At least 40% of newly diagnosed cancers in the United States are potentially avoidable, including 19% attributed to smoking and at least 18% due to excess body weight, alcohol consumption, poor nutrition, and physical inactivity. (3) Key interventions to reduce cancer risk include smoking cessation; limiting or eliminating alcohol intake; improving nutrition; addressing insulin resistance and metabolic syndrome; engaging in moderate physical activity; and supplementing with epigallocatechin gallate (EGCG, found in green tea), curcumin (a polyphenol derived from turmeric), vitamin D3, and omega-3 fatty acids—the foundation of the Root Protocols. (3)
The DO-HEALTH trial was a 3-year, multicenter, double-blind randomized controlled trial (RCT) using a 2 × 2 × 2 factorial design to evaluate the individual and combined effects of supplemental vitamin D3 (2000 IU/day), marine omega-3 fatty acids (1 g/day), and a simple home-based strength exercise program. Notably, the dose of vitamin D and Omega-3 fatty acids was exceptionaly low (? designed to be a negative study). These interventions were compared with a placebo and a control group. (4, 5) Each intervention independently reduced cancer risk, but the combination was synergistic and highly effective, with an adjusted hazard ratio of 0.39.
Although reported as a negative study, the NIH-funded Vitamin D and Omega-3 Trial (VITAL) further supported the protective effect of vitamin D on cancer mortality, showing lower rates of cancer-related deaths among participants randomized to vitamin D3 versus placebo (HR, 0.72; 95% CI, 0.52–1.00). (6)
Many other nutraceuticals appear to be highly effective in preventing cancer. These are listed below. With the assistance of artificial intelligence (Perplexity), we developed a series of nutraceutical-based protocols (ROOT Protocols) to support cancer prevention. Because most cancers occur in individuals older than 65 years due to cumulative risk exposure, these protocols—particularly ROOT 3 through ROOT 5—may be especially beneficial for this population.
Germline Cancer Syndromes and Preventive Considerations
Certain germline mutations—inherited changes in DNA present in all cells—substantially increase cancer risk by disrupting normal cellular regulation and DNA repair mechanisms. These mutations account for approximately 5% to 10% of all cancers and are associated with specific gene variants that predispose individuals to distinct cancer types and hereditary cancer syndromes:
BRCA1/BRCA2 mutations: associated with up to a 70% lifetime risk of breast cancer in women
TP53 mutations (Li-Fraumeni syndrome): associated with a >50% lifetime risk of multiple cancers
Lynch syndrome: confers a 50% to 70% lifetime risk of colorectal cancer and up to 60% risk of endometrial cancer in women
APC mutations (familial adenomatous polyposis): associated with a nearly 100% lifetime risk of colorectal cancer without intervention
In addition to genetic screening, surgery, and other interventions, the ROOT 6 or ROOT 9 protocols may be appropriate for patients with inherited cancer syndromes. However, these nutraceuticals and repurposed drug protocols should be integrated into a comprehensive clinical management plan.
The following nutraceuticals and repurposed drugs demonstrate cancer-preventive potential:
Green Tea Extract (EGCG)
EGCG, a polyphenol found in green tea, exhibits multifaceted anticancer properties by targeting tumor biology, modulating the immune system, and influencing metabolic pathways. (7) Preclinical and clinical studies support the role of EGCG in cancer prevention. (8-15)
Mechanisms of action in cancer prevention
Immune system modulation
Enhances cytotoxic immune responses: EGCG promotes antitumor activity of CD8+ T cells and natural killer (NK) cells by increasing their infiltration into tumors and boosting granzyme/perforin-mediated apoptosis. (7) It also stimulates dendritic cell maturation, improving antigen presentation.
Suppresses immunosuppressive cells: EGCG reduces myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), which typically inhibit immune responses. (7) It has been shown to increase the ratio of active cytotoxic T lymphocytes to Tregs in tumors, effectively converting “cold” tumors to “hot” tumors and significantly improving responsiveness to antitumor immunotherapy. (16)
PD-1 axis and TLR4 pathway: EGCG exerts anticancer effects by enhancing antitumor immunity via the programmed death 1 (PD-1) axis and Toll-like receptor 4 (TLR4) signaling pathways. (17, 18)
Reprograms tumor-associated macrophages (TAMs): By downregulating chemokines such as CCL2 and CSF-1, EGCG limits TAM recruitment and shifts their polarization from pro-tumorigenic (M2) to antitumor (M1) phenotypes. (7)
Metabolic disruption in cancer cells
Inhibits glucose metabolism: EGCG blocks glucose uptake by suppressing glucose transporter 1 (GLUT1) and targets hexokinase 2 (HK2), a key glycolytic enzyme, thereby reducing ATP production. (7, 11) This disrupts the Warburg effect—a hallmark of cancer metabolism.
Targets glutamine and fatty acid pathways: EGCG interferes with glutaminase and fatty acid synthase, enzymes critical for tumor growth under nutrient stress.
Direct antitumor effects
Induces apoptosis and cell cycle arrest: EGCG upregulates pro-apoptotic proteins (eg, cytochrome c) and downregulates anti-apoptotic proteins such as Bcl-2, while arresting the cell cycle at the G1 phase via p21 activation. (7, 9)
Inhibits angiogenesis via VEGF: EGCG significantly reduces the expression of vascular endothelial growth factor (VEGF) and its receptors, suppressing angiogenesis—a key process in tumor progression and a target in both cancer prevention and treatment.
Inhibits oncogenic signaling. EGCG inhibits the Wnt pathway by promoting β-catenin phosphorylation and degradation and also suppresses the Sonic Hedgehog pathway by targeting associated transcription factors.
Modulates epigenetics: EGCG inhibits DNA methyltransferases and histone deacetylases, reversing hypermethylation of tumor suppressor genes. (7)
Targets cancer stem cells: Green tea extract has been shown to suppress CSCs. (19, 20)
Curcumin
Curcumin, a polyphenol derived from turmeric (Curcuma longa), has demonstrated significant potential in cancer prevention through its ability to modulate multiple molecular pathways involved in carcinogenesis. Its anti-inflammatory, antioxidant, and antiproliferative properties collectively disrupt cancer development and progression. (21-25)
Mechanisms of action in cancer prevention
Modulation of signaling pathways
Curcumin targets several critical pathways implicated in cancer cell survival and growth:
PI3K/AKT/mTOR pathway: Curcumin inhibits AKT phosphorylation, suppresses cyclin D1, and enhances PTEN expression, promoting apoptosis in gastric and ovarian cancers. (26, 27)
Wnt/β-catenin pathway: Curcumin blocks β-catenin nuclear translocation, downregulating cyclin D1 and c-Myc in lung and breast cancers. (26)
NF-κB pathway: Inhibition of nuclear factor κB (NF-κB) reduces the production of inflammatory cytokines (eg, COX-2, VEGF) and disrupts survival signals in hepatoma and breast cancer cells. (26, 28)
Hedgehog and JAK/STAT3 pathways: Curcumin suppresses GLI1 expression in glioma and prostate cancers and inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), thereby reducing angiogenesis in lung cancer. (26)
Pro-apoptotic and antiproliferative effects
Curcumin upregulates pro-apoptotic proteins (eg, Bcl-2–associated X protein [BAX], cleaved caspase-3 and -9) and downregulates anti-apoptotic factors (eg, Bcl-2, Bcl-xL), particularly in breast, prostate, and thyroid cancers. It also induces cell cycle arrest and autophagy in glioblastoma. (26)
Anti-inflammatory and antioxidant activity
By suppressing reactive oxygen species (ROS) and inflammatory mediators, such as CXCL1 and CXCL2, curcumin mitigates chronic inflammation associated with cancer initiation.
Vitamin D
Vitamin D exhibits multifaceted mechanisms in cancer prevention, targeting multiple stages of carcinogenesis from initial DNA damage to metastatic spread. Its actions span anti-inflammatory, antioxidant, DNA repair, cell cycle regulation, and immunomodulatory pathways, supported by preclinical and epidemiological evidence. (29-38)
Mechanisms of action in cancer prevention
Anti-inflammatory effects
NFκB pathway inhibition: Vitamin D suppresses NFκB signaling by stabilizing IκBα proteins and blocking IKK activation, thereby reducing proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages, fibroblasts, and cancer cells. (36, 39)
Mitogen-activated protein kinase (MAPK) pathway modulation: By upregulating MAPK phosphatase 5 (MKP-5) and MAPK phosphatase 1 (MKP-1), vitamin D inhibits p38 MAPK-mediated inflammation, particularly in prostate and colon cancers. (36, 39)
Immune cell interaction: In tumor microenvironments, vitamin D reduces the production of TNF-α and IL-6 in immune cells co-cultured with cancer cells. (39)
Antioxidant defense
Nrf2-Keap1 activation: Vitamin D enhances antioxidant capacity by activating the Nrf2 pathway, increasing glutathione (GSH) levels, and reducing oxidative stress markers such as nitric oxide (NO). (36)
ROS neutralization: It reduces reactive oxygen species that contribute to DNA damage during tumor initiation. (36, 39)
DNA damage repair
Gene upregulation: enhances expression of DNA repair genes, including TP53, BRCA1, ATM, and GADD45α, in breast, ovarian, and prostate cancers (36, 39)
Protein stabilization: prevents degradation of DNA repair proteins such as 53BP1 by inhibiting cathepsin L activity (39)
Cell cycle arrest and apoptosis
G1/S phase arrest: downregulates cyclin-dependent kinases (CDKs) and upregulates CDK inhibitors (eg, p21), thereby blocking proliferation in colorectal and breast cancers (33, 36)
Apoptosis induction: activates pro-apoptotic proteins (eg, Bax) and inhibits anti-apoptotic proteins such as Bcl-2, while modulating caspase activity in multiple cancer types (33, 36)
Angiogenesis and metastasis suppression
VEGF inhibition: reduces vascular endothelial growth factor synthesis, limiting tumor blood vessel formation (33, 36)
EMT blockade: inhibits epithelial-mesenchymal transition (EMT), a critical step in metastasis, through regulation of transforming growth factor β (TGF-β) and Wnt/β-catenin pathways (33, 39)
Immunomodulation
T-cell regulation: enhances antitumor immune responses by promoting T-cell differentiation and reducing immunosuppressive cytokine production (33, 40)
Macrophage polarization: shifts macrophages toward antitumor M1 phenotypes within the tumor microenvironment
Dose of Vitamin D
In patients with cancer we target a Vitamin D3 level, close to 100 ng/l. This is a controversial topic, and it is unclear whether a level of between 100-150 ng/ml is harmful if serum calcium and PTH levels are monitored (Coimbra protocol).(41-43) It is likely that the target level differs for maintaining good health and preventing cancer. There is no single universally accepted “target” 25(OH)D level for cancer prevention, but most of the stronger epidemiologic and interventional data point to benefit once levels are at least around 30–40 ng/mL, with many groups aiming for a level of 40 -60 ng/mL as a pragmatic threshold.(44, 45)
Omega-3 Fatty Acids
Mechanisms of action in cancer prevention
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exhibit multifaceted mechanisms in cancer prevention, supported by experimental and clinical evidence. (46-51) These mechanisms range from modulating inflammation to directly inducing cancer cell death, as outlined below.
Anti-inflammatory and eicosanoid modulation
Omega-3 fatty acids compete with proinflammatory omega-6 fatty acids for enzymatic conversion, reducing the production of pro-angiogenic and pro-survival mediators such as prostaglandin E₂ (PGE₂) and VEGF. (48, 52, 53) By activating peroxisome proliferator–activated receptors (PPARs), they suppress NF-κB signaling, thereby reducing inflammatory cytokines and modulating apoptotic proteins such as Bcl-2 and Bcl-xS. (52, 54) This shift in the omega-6/omega-3 ratio counteracts the pro-tumorigenic environment promoted by Western diets. (53, 55)
Apoptosis induction
Lipid peroxidation: generates ROS that damage cancer cell membranes (52)
Mitochondrial modulation: disrupts calcium homeostasis and enhances ROS production, leading to mitochondrial dysfunction (52, 55)
p53 activation: promotes tumor suppressor pathways that induce programmed cell death (52, 53)
Ferroptosis activation
In acidic tumor microenvironments, omega-3 fatty acids overwhelm cancer cells’ antioxidant defenses, causing lethal lipid oxidation (ferroptosis). This process is amplified when lipid metabolism inhibitors block the formation of protective lipid droplets. (52, 56)
Cell Proliferation and metastasis suppression
Omega-3 fatty acids inhibit growth signaling pathways, including epidermal growth factor receptor (EGFR) and Ras/mitogen-activated protein kinase (MAPK), and induce cell cycle arrest. They also reduce metastasis by suppressing enzymes such as matrix metalloproteinases involved in tumor invasion. (52)
Membrane composition and signaling
Incorporation of omega-3 fatty acids into cell membranes alters lipid raft structure, disrupting pro-survival signaling and reducing inflammation-associated carcinogenesis. This membrane remodeling also impedes tumor cell communication and growth. (52)
Immunomodulation
By lowering oxidative stress and inflammatory cytokines (eg, IL-6, TNF-α), omega-3 fatty acids create an antitumor immune environment. (48) This effect is enhanced by co-nutrients such as vitamin D.
Berberine
Mechanisms of action in cancer prevention
Berberine, a natural isoquinoline alkaloid, exerts multitarget anticancer effects by modulating critical cellular processes and signaling pathways. Its chemopreventive mechanisms reflect a polypharmacological approach targeting multiple hallmarks of cancer. (57-60)
Apoptosis induction
Berberine activates both intrinsic and extrinsic apoptosis pathways by:
Upregulating pro-apoptotic BAX while suppressing anti-apoptotic BCL2 and BCL2L1 (57, 61, 62)
Increasing caspase-8 activity and TNF-α expression in cervical cancer cells (57, 61)
Enhancing p53 tumor suppressor activity in breast and liver cancers (61)
Cell cycle arrest
Berberine induces cell cycle blockade at specific checkpoints:
G2/M phase arrest in oral squamous cell carcinoma and cervical cancer cells (62)
G0/G1 phase inhibition in leukemia models through differentiation suppression (57, 58, 62)
Cyclin-dependent kinase regulation via upregulation of CDKN1B in breast cancer (61)
Anti-angiogenesis and metastasis suppression
Berberine disrupts tumor microenvironment support by:
Inhibiting VEGF, IL-6, and matrix metalloproteinases (MMPs), thereby preventing neovascularization (58, 62)
Suppressing epithelial-mesenchymal transition (EMT) through upregulation of E-cadherin (57, 60, 63)
Reducing metastatic potential in nasopharyngeal carcinoma via inhibition of STAT3 (61)
Key signaling pathway modulation
Berberine targets multiple oncogenic pathways: (57, 58, 60, 63)
Downregulates EGFR expression
Inhibits phosphorylation of p38 and extracellular signal-regulated kinase (ERK)
Suppresses AKT activation
Inhibits telomerase activity via regulation of human telomerase reverse transcriptase (hTERT)
Berberine suppresses colon and gastric cancer cell growth via apoptosis, autophagy, and cell‑cycle arrest; it is being explored for colorectal cancer prevention in high‑risk patients. (64)
Sulforaphane
Mechanisms of action in cancer prevention
Sulforaphane (SFN), a bioactive compound found in cruciferous vegetables such as broccoli, exhibits multifaceted anticancer properties through several interconnected mechanisms. (65-68) Its ability to modulate epigenetic pathways, induce apoptosis, arrest the cell cycle, and enhance detoxification processes makes it a potent chemopreventive agent. Below is a summary of its key mechanisms:
Epigenetic modulation
Histone deacetylase (HDAC) inhibition: SFN inhibits HDAC activity, resulting in increased histone acetylation and the reactivation of tumor suppressor genes. This promotes apoptosis and cell cycle arrest in cancer cells. (66, 69, 70)
DNA methylation regulation: SFN reduces DNA methyltransferase (DNMT) activity, thereby reversing the hypermethylation of tumor suppressor gene promoters (eg, Cyclin D2 in prostate cancer). (67, 70)
Noncoding RNA regulation: SFN modulates microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which regulate apoptosis, proliferation, and differentiation. For example, it upregulates the tumor-suppressive miR-200c to target CSCs. (66, 70)
Apoptosis induction
Pro-apoptotic signaling: SFN upregulates pro-apoptotic proteins, such as BAX, and downregulates the anti-apoptotic proteins Bcl-2 and Bcl-xL, thereby triggering the release of mitochondrial cytochrome c and the activation of caspase-3. (70, 71)
Caspase activation: SFN activates caspases-3, -8, and -9, leading to the cleavage of poly(ADP-ribose) polymerase (PARP) and programmed cell death. (67, 70)
STAT3 and NF-κB inhibition: By suppressing oncogenic pathways such as STAT3 and NF-κB, SFN reduces inflammation and cancer cell survival. (69, 70)
Cell cycle arrest
G2/M phase arrest: SFN inhibits CDK1 and upregulates p21 and p27, halting cancer cell proliferation in the G2/M phase. (67, 71)
S-phase arrest: In lung cancer cells, SFN induces S-phase arrest through ROS-mediated DNA damage. (67)
Detoxification and antioxidant pathways
Phase II enzyme induction: SFN induces phase II detoxification enzymes such as glutathione S-transferase (GST) and NAD(P)H quinone oxidoreductase 1 (NQO1), which help neutralize carcinogens. (67, 71)
Phase I enzyme inhibition: SFN suppresses cytochrome P450 enzymes, reducing carcinogen activation. (67, 70)
Targeting cancer stem cells
SFN suppresses CSC self-renewal by modulating Wnt/β-catenin and NF-κB pathways, reducing tumorigenicity and metastasis in oral and other cancers. (70, 71)
Anti-angiogenesis and anti-inflammation
SFN inhibits VEGF and fibroblast growth factor 2 (FGF2), blocking tumor vascularization. It also reduces proinflammatory cytokines such as TNF-α and interleukin-1β (IL-1β), thereby curbing tumor-promoting inflammation. (67, 69)
In summary, sulforaphane’s chemopreventive effects stem from its ability to simultaneously target multiple hallmarks of cancer, including epigenetic dysregulation, uncontrolled proliferation, and evasion of cell death. Preclinical and clinical studies underscore its potential as an adjunct to conventional therapies, particularly in breast, prostate, and colon cancers. (66, 67, 70, 72)
Root Protocols
As demonstrated above, the ranking of EGCG, curcumin, vitamin D, omega-3 fatty acids, berberine, and sulforaphane reflects their documented efficacy in cancer prevention. When added sequentially, these agents form the Root Preventive Protocols, with each step providing a greater reduction in cancer risk. The Root Protocols were developed using artificial intelligence (AI). To replicate these results using AI, it is essential to begin with the baseline and add agents stepwise. Initiating analysis with all nine agents simultaneously will not yield the same outcome; this reflects the sequential logic inherent in AI-based modeling.
Our baseline begins with three agents: EGCG, curcumin, and vitamin D. Each subsequent addition to this foundation further enhances cancer risk reduction (Table 1).
Everyone—from young adults to centenarians—may benefit from the three foundational supplements (EGCG, vitamin D, and curcumin) to help reduce cancer risk. Projections for 2025 indicate a substantial cancer burden. Root 4 is the recommended basic protocol for older adults, while those at higher risk may consider Root 5 or Root 6. Table 2 outlines cancer-specific risk reductions, targeted pathways, and synergistic mechanisms associated with Root 4. To further clarify its mechanistic basis, Table 3 highlights pathway-specific interactions and synergies among Root 4 components, illustrating how their combined effects modulate cancer-related signaling. All components of these protocols are nutraceuticals and are available over the counter.
For those with inherited cancer syndromes or a significantly elevated risk, adding the pharmaceutical drugs celecoxib, (73-75) ivermectin, (76-81) and mebendazole (82-88) to Root 6 creates Root 9, the most comprehensive protocol offering the highest level of protection.
Root 4 Safety Profile
Suggested dosing ranges for Root 4 components are summarized in Table 4. The following safety considerations apply to these agents:
EGCG: Safe at doses up to 800 mg/day. Mild gastrointestinal distress may occur at higher doses; hepatotoxicity is rare and typically associated with doses exceeding 800 mg/day.
Curcumin: Well tolerated at doses up to 8 g/day. Enteric-coated formulations may reduce nausea. Potential drug interactions may occur, particularly with anticoagulants and antiplatelet agents.
Vitamin D: Considered safe up to 5 000 IU/day. Serum levels should be monitored to avoid hypercalcemia.
Omega-3 fatty acids: May increase bleeding risk at doses above 3 g/day. Use with caution in patients taking anticoagulants or antiplatelet agents.
Adverse events:
Mild gastrointestinal symptoms (15%)
Headaches (5%)
Fatigue (3%)
Disclaimer: Root 4 is not a substitute for medical treatment. Consult a healthcare provider before use, especially if pregnant, immunocompromised, or taking anticoagulants. Discontinue use if adverse reactions occur.
Root 9: Celecoxib, Ivermectin, and Mebendazole for Prevention of Inherited Cancer
Ivermectin
Ivermectin, an FDA-approved antiparasitic drug, has demonstrated broad-spectrum anticancer effects in preclinical studies, including activity against various types of cancer via multiple mechanisms. Although research specifically addressing inherited cancers is limited, these findings suggest potential relevance for certain genetic cancer syndromes.
Mechanisms of action in cancer prevention
Ivermectin modulates several cancer-related pathways:
WNT–TCF pathway inhibition: Blocks signaling critical in colorectal and other cancers associated with familial adenomatous polyposis (FAP) (89)
PAK1 kinase regulation: Suppresses tumor growth and metastasis in breast cancer models, relevant for BRCA-mutated cancers (90)
Mitochondrial dysfunction induction: Increases ROS production and promotes apoptosis, as demonstrated in pancreatic cancer studies (91)
Cancer stem cell suppression: Reduces stem-like cell populations in breast cancer models (81)
Mebendazole
Mebendazole, an FDA-approved anthelmintic drug, has shown preclinical potential in treating inherited cancers by targeting multiple pathways involved in tumor growth and chemoresistance. Inherited cancers, such as FAP linked to APC gene mutations, have been studied in preclinical models using mebendazole. The following summarizes key findings.
Preclinical evidence in genetic models
In the ApcMin/+ mouse model (a genetic model for FAP), mebendazole reduced intestinal tumor numbers by 56% as a single agent and up to 90% when combined with sulindac, a nonsteroidal anti-inflammatory drug (NSAID). (88) This combination also suppressed angiogenesis by inhibiting VEGFR2 kinase activity and reduced microvessel density in polyps. (83, 88)
Mechanisms relevant to inherited cancers
Hypoxia pathway inhibition: Mebendazole disrupts hypoxia-inducible factors (HIF-1α, HIF-2α, and HIF-1β), which drive tumor adaptation to low-oxygen environments commonly seen in solid tumors. (92) This inhibition reduces chemoresistance and metastatic potential, which is critical in aggressive inherited cancers such as BRCA-associated breast and ovarian cancers. (92, 93)
Tubulin disruption and apoptosis: By depolymerizing tubulin, mebendazole induces mitotic arrest and apoptosis in cancer cells, including those resistant to treatment. (83) It activates caspases and downregulates survival pathways such as AKT and STAT3. (83, 94)
Cancer stem cell targeting: Mebendazole reduces stem-like phenotypes in triple-negative breast cancer (TNBC) by inhibiting integrin β4 (ITGβ4), thereby decreasing metastasis and improving response to radiation. (92)
Clinical trials and safety
A phase 2a trial with advanced gastrointestinal cancers found mebendazole safe at doses up to 4 g/day but noted progressive disease in all participants. (95) These findings highlight the need for combination therapies rather than monotherapy. (88, 95)
Considerations for inherited cancers
Inherited cancers often involve mutations (eg, APC, BRCA) that drive aggressive growth and resistance to therapy. Mebendazole’s multitarget mechanisms address these hallmarks, though clinical success will likely depend on personalized dosing and combination regimens. (88, 95)
Celecoxib
Celecoxib, a selective COX-2 inhibitor, has demonstrated promise in treating inherited cancers, particularly FAP (familial adenomatous polyposis), an autosomal dominant condition that predisposes individuals to colorectal cancer.
Use of celecoxib for FAP
Celecoxib is FDA-approved as an adjunctive therapy for FAP to reduce the number and size of adenomatous polyps in the colon and rectum. In clinical trials, patients taking 400 mg twice daily experienced a 28% reduction in polyps, compared with a 5% reduction in placebo groups.
This reduction in polyp burden may delay or reduce the need for surgical interventions, although its direct impact on cancer prevention remains under investigation.
Mechanisms of action
Celecoxib works by inhibiting the COX-2 enzyme, which is linked to inflammation and tumor development. COX-2 is expressed throughout all stages of human colon carcinogenesis, making celecoxib effective not only for reducing polyps but also potentially for chemoprevention.
Emerging evidence for broader applications
Research suggests that celecoxib may improve disease-free survival in patients with genetic mutations associated with colorectal cancer, such as those involving the PIK3CA gene. In these cases, celecoxib appears to enhance outcomes when used post-surgery. (96, 97)
Studies also indicate that celecoxib can act as a mitochondrial pro-oxidant, increasing ROS production to induce apoptosis in cancer cells. (96, 98, 99)
Considerations and limitations
While celecoxib has shown efficacy in reducing polyp formation and aiding certain subsets of cancer patients, its role in outright cancer prevention is not fully established. Clinical trials continue to evaluate its long-term benefits and safety profile, particularly regarding gastrointestinal side effects.
Disclaimer: Root 9 is not a substitute for medical treatment. Consult a healthcare provider with expertise in inherited cancers before using this protocol. Discontinue use if adverse reactions occur.
Aged Garlic Extract and the ROOT + protocols
As discussed below, aged garlic extract (AGE) has powerful cancer prevention properties. When AGE is added to the root protocols it is known as the ROOT 3+, ROOT 4+, ROOT 5+, ROOT 6+ and ROOT 9+ protocols.
Aged garlic extract (AGE) shows promising cancer‑protective effects in cell and animal models and some early human studies, mainly through antioxidant, anti‑inflammatory, immune‑modulating, and pro‑apoptotic mechanisms.(100-102) AGE is produced by aging raw garlic in aqueous ethanol for months, converting unstable, harsh compounds like allicin into more stable, less irritating, water‑soluble organosulfur compounds. Major components include S‑allyl cysteine (SAC), S‑allyl mercaptocysteine (SAMC), and related organosulfur compounds, along with phenolics and other antioxidants. These compounds have high bioavailability and relatively low toxicity compared with some constituents of raw garlic, which may allow chronic use at doses relevant to chemoprevention.
A randomized trial in patients with colorectal adenomas found that one year of high‑dose AGE significantly reduced the number and size of adenomas compared with low‑dose AGE, suggesting a potential suppressive effect on adenoma progression. (103, 104) Small clinical studies in patients with advanced cancers reported that AGE helped maintain or enhance natural killer (NK) cell activity.
AGE and SAC enhance endogenous antioxidant defenses, increasing glutathione (GSH) and phase II detoxifying enzymes such as glutathione S‑transferase (GST) and NAD(P)H:quinone oxidoreductase, which can improve detoxification of carcinogens and limit DNA damage. GE activates the Nrf2 pathway and downregulates pro‑oxidant enzymes (including inducible nitric oxide synthase), thereby reducing oxidative stress and potentially decreasing mutagenesis and cancer initiation.
In multiple cancer cell lines, AGE and garlic‑derived organosulfur compounds induce cell cycle arrest (often at G2/M or G0/G1) and promote apoptosis via modulation of key regulators such as p53, p21, Bax, Bcl‑2, Fas, and caspases. AGE can inhibit angiogenesis by limiting endothelial cell motility, proliferation, and tube formation, thereby reducing tumor neovascularization required for growth and metastasis.
AGE is generally well tolerated, with fewer gastrointestinal and odor issues than raw garlic, but it can interact with antiplatelet or anticoagulant therapy and may increase bleeding risk. The suggested dose is 600mg twice daily.
Conclusion
The Root Protocols provide a mechanistically grounded, AI-informed framework for cancer prevention. By combining well-studied nutraceuticals and repurposed drugs, these protocols target multiple pathways in carcinogenesis, offering a tiered approach adaptable to individual risk profiles.
Foundational protocols such as Root 3 and Root 4 may support cancer prevention in the general population, while advanced tiers (Root 6 and Root 9) offer added protection for individuals at elevated risk, including those with inherited cancer syndromes. Although clinical trials are needed to validate long-term efficacy, the strong mechanistic rationale, favorable safety data, and accessibility of these compounds support their thoughtful integration into preventive care. Future studies evaluating real-world outcomes and identifying optimal patient subgroups will further refine the clinical utility of these protocols. Implemented under clinical guidance, the ROOT Protocols may provide a low-risk, evidence-informed approach to mitigating the rising burden of cancer.
New Here?
Start with the: Cancer and the Metabolic Library
Medical Disclaimer: The discussion of repurposed medications and nutraceuticals in this article is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan. Please see the full Medical Disclaimer on the introductory page to Marik’s Cancer & Metabolic Healing Playbook.
References
1. Siegel RL, Giaquinto AN, Jemal A. Cancer Statistics, 2024. CA Cancer J Clin. 2024.
2. Sung H, Jiang C, Bandi P, Minihan A, Fidler-Benaoudia M, Islami F, et al. Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data. Lancet Public Health. 2024;9(8):e583–e93.
3. Cancer Facts & Figures 2023. Atlanta; 2023.
4. Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW. Effect of Vitamin D supplementation, omega-3 fatty acid supplementation, or a strengh-training excercise program on clinical outcomes in older adults. the DO-HEALTH randomized clinical trial. JAMA. 2020;324:1855–68.
5. Bischoff-Ferrari HA, Willett WC, Manson JE, Dawson-Hughes B, Manz MG, Theller R, et al. Combined Vitamin D, omega-3 fatty acids, and a simple home exercise program may reduce cancer risk among active adults aged 70 and older: A randomized clinical trial. Front. Aging. 2022;3:852643.
6. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J Med. 2019;380(1):33–44.
7. Li D, Cao D, Sun Y, Cui Y, Zhang Y, Jiang J, et al. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy. Front Immunol. 2024;15:1331641.
8. Sharifi-Rad M, Pezzani R, Redaelli M, Zorzan M, Imran M, Ahmed KA, et al. Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer. Molecules. 2020;25(3).
9. Du GJ, Zhang Z, Wen XD, Yu C, Calway T, Yuan CS, et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012;4(11):1679–91.
10. Syed DN, Afaq F, Kweon MH, Hadi N, Bhatia N, Spiegelman VS, et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene. 2007;26(5):673–82.
11. Chen BH, Hsieh CH, Tsai SY, Wang CY, Wang CC. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci Rep. 2020;10(1):5163.
12. Kallifatidis G, Hoy JJ, Lokeshwar BL. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol. 2016;40-41:160–9.
13. Farhan M. Green Tea Catechins: Nature’s Way of Preventing and Treating Cancer. Int. J Mol. Sci. 2022;23(18).
14. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 2010;5:14.
15. Li XX, Liu C, Dong SL, Ou CS, Lu JL, Ye JH. Anticarcinogenic potentials of tea catechins. Front. Nutr. 2022;9:1060783.
16. Song Q, Zhang G, Wang B, Cao G, Li D, Wang Y, et al. Reinforcing the combinational immuno-oncotherapy of switching “cold” tumor to “hot” by responsive penetrating nanogels. ACS Appl. Mater. Interface. 2021;13:36824–38.
17. Menon DR, Li Y, Yamauchi T, Osborne DG, Vaddi PK, wempe MF, et al. EGCG inhibits tumor growth in melanoma by targeting JAK-STAT signaling andits downstream PD-L1/PD-L2-PD1 axis in tumors and enhancing cytotoxic T-cell responses. Pharmaceuticals. 2021;14:1081.
18. McCarty MF, Iloki-Assanga S, Lujany LML. Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia. Med Hypotheses. 2019;132:109326.
19. Lin CH, Shen YA, Hung PH, Yu YB, Chen YJ. Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines. BMC Complement Altern Med. 2012;12:201.
20. Bonuccelli G, Sotgia F, Lisanti MP. Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways. Aging (Albany NY). 2018;10(8):1867–83.
21. Panahi Y, Darvishi B, Ghanei M, Jowzi N, Beiraghdar F, Varnamkhasti BS. Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-kB pathway. Cytokine Growth Factor Rev. 2016;28:21–9.
22. Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012;21(5):407–12.
23. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728–69.
24. Zheng J, Zhou Y, Li Y, Xu DP, Li S, Li HB. Spices for Prevention and Treatment of Cancers. Nutrients. 2016;8(8).
25. Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010;5(1):61–74.
26. Ameer SF, Mohamed MY, Elzubair QA, Sharif EAM, Ibrahim WN. Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment? Front Oncol. 2024;14:1438040.
27. Zoi V, Kyritsis AP, Galani V, Lazari D, Sioka C, Voulgaris S, et al. The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway. Cancers (Basel). 2024;16(8).
28. Zoi V, Galani V, Lianos GD, Voulgaris S, Kyritsis AP, Alexiou GA. The Role of Curcumin in Cancer Treatment. Biomedicines. 2021;9(9).
29. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. American Journal of Clinical Nutrition. 2007;85(6):1586–91.
30. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468–83.
31. Carlberg C, Velleuer E. Vitamin D and the risk for cancer: A molecular analysis. Biochem. Pharmacol. 2022;196:114735.
32. Zhang Y, Fang F, Tang J, Jia L, Feng Y, Xu P, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019;366:l4673.
33. Dallavalasa S, Tulimilli SV, Bettada VG, Karnik M, Uthaiah CA, Anantharaju PG, et al. Vitamin D in Cancer Prevention and Treatment: A Review of Epidemiological, Preclinical, and Cellular Studies. Cancers (Basel). 2024;16(18).
34. Robsahm TE, Schwartz GG, Tretli S. The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation. Cancers (Basel). 2013;5(4):1439–55.
35. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 2014(1):CD007470.
36. Rong K, He Q, Chen S, Yu Y, Mei L, Mi Y, et al. The mechanism of vitamin D3 in preventing colorectal cancer through network pharmacology. Front Pharmacol. 2023;14:1192210.
37. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33–44.
38. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat. Rev Cancer. 2014;14(5):342–57.
39. Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):1–14.
40. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441(1):61–76.
41. Finamor DC, Sinigaglia-Coimbra R, Neves LC, Gutierrez M, Silva JJ, Torres LD, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermatoendocrinol. 2013;5(1):222–34.
42. Amon U, Yaguboglu R, Ennis M, Holick MF, Amon J. Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”. Nutrients. 2022;14(8).
43. Lemke D, Klement RJ, Schweiger F, Schweiger B, Spitz J. Vitamin D resistance as a possible cause of autoimmune diseases: A hypothesis confirmed by a therapeutic high-dose Vitamin D protocol. Front. Immunol. 2021;12:655739.
44. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2014;810:500–25.
45. Ekmekcioglu C, Poteser M. The Optimal Protective 25-Hydroxyvitamin D Level for Different Health Outcomes in Adults: A Brief Summary of Dose-Response Meta-Analyses. Metabolites. 2025;15(4).
46. Kim S, Sandler DP, Galanko J, Martin C, Sandler RS. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. Am J Epidemiol. 2010;171(9):969–79.
47. Hoang T, Myung SK, Pham TT. Gynecological cancer and omega-3 fatty acid intakes: Meta-analysis. Asia Pac J Clin Nutr. 2021;30(1):153–62.
48. Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res. 2015;17(1):62.
49. Vasudevan A, Yu Y, Banerjee S, Woods J, Farhana L, Rajendra SG, et al. Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. Cancer Prev Res (Phila). 2014;7(11):1138–48.
50. Signori C, El-Bayoumy K, Russo J, Thompson HJ, Richie JP, Hartman TJ, et al. Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Research. 2011;71(19):6091–6.
51. Manson JE, Cook NR. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N. Engl. J. Med. 2018.
52. Wendel M, Heller AR. Anticancer actions of omega-3 fatty acids--current state and future perspectives. Anticancer Agents Med Chem. 2009;9(4):457–70.
53. Pizato N. Omega-3 Fatty Acids-Related Cancer Prevention: An Opinion. Biomedical Journal of Scientific & Technical Research 2018;11:8883–4.
54. Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care. 2013;16(2):156–61.
55. Kao CL, Hung YC, Liu CM. The Pharmacological Effect of Omega-3 Fatty Acids Prevent Cancer Progression in Colon and Breast Cancer. Austin Journal of Nutrition food Sciences. 2017;5:1090.
56. Delesderrier E, Monteiro JDC, Freitas S, Pinheiro IC, Batista MS, Citelli M. Can Iron and Polyunsaturated Fatty Acid Supplementation Induce Ferroptosis? Cell Physiol Biochem. 2023;57(S1):24–41.
57. Wang Y, Liu Y, Du X, Ma H, Yao J. The anti-cancer mechanisms of berberine: A review. Cancer Management and Research. 2020;12:695–702.
58. Zhang C, Sheng J, Li G, Zhao L, Wang Y, Yang W, et al. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 2019;10:1461.
59. Samadi P, sarvarian P, Gholipour E, Asenjan KS, Aghebati-Maleki L, Motavalli R. Berberine: A novel therapeutic strategy for cancer. IUBMB Lefe. 2020;72:2065–79.
60. Almatroodi SA, Alsahli MA, Rahmani AH. Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways. Molecules. 2022;27(18).
61. Guo P, Cai C, Wu X, Fan X, Huang W, Zhou J, et al. An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology. Front Pharmacol. 2019;10:857.
62. Li Q, Zhao H, Chen W, Huang P. Berberine induces apoptosis and arrests the cell cycle in multiple cancer cell lines. Arch Med Sci. 2023;19(5):1530–7.
63. Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: An update review. Molecules. 2022;27:4523.
64. Davoodvandi A, Sadeghi S, Alavi SMA, Alavi SS, Jafari A, Khan H, et al. The therapeutic effects of berberine for gastrointestinal cancers. Asia Pac J Clin Oncol. 2024;20(2):152–67.
65. Elkashty OA, Tran SD. Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment. Curr Med Sci. 2021;41(2):250–69.
66. Asif Ali M, Khan N, Kaleem N, Ahmad W, Alharethi SH, Alharbi B, et al. Anticancer properties of sulforaphane: current insights at the molecular level. Front Oncol. 2023;13:1168321.
67. Coutinho LL, Junior TCT, Rangel MC. Sulforaphane: An emergent anti-cancer stem cell agent. Front Oncol. 2023;13:1089115.
68. Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs. 2015;33(2):480–9.
69. Jabbarzadeh Kaboli P, Afzalipour Khoshkbejari M, Mohammadi M, Abiri A, Mokhtarian R, Vazifemand R, et al. Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives. Biomed Pharmacother. 2020;121:109635.
70. Nandini DB, Rao RS, Deepak BS, Reddy PB. Sulforaphane in broccoli: The green chemoprevention!! Role in cancer prevention and therapy. J Oral Maxillofac Pathol. 2020;24(2):405.
71. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007;28(9):1343–54.
72. ElKhalifa D, Al-Ziftawi N, Awaisu A, Alali F, Khalil A. Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials. Front Oncol. 2023;13:1251895.
73. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664–74.
74. Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin. Cancer Res. 2005;11(19 Pt 1):6807–15.
75. Sareddy GR, Kesanakurti D, Kirti PB, Babu PP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wntb-catenin/Tcf signaling pathway in human glioblastoma cells. Neurochem. Res. 2013;38(11):2313–22.
76. Juarez M, Schcolnik-Cabrera A, Duenas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am. J. Cancer Res. 2018;8:317–31.
77. Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochemical and Biophysical Research Communications. 2016;480(3):415–21.
78. Liu J, Liang H, Chen C, Wang X, Qu F, Wang H. Ivermectin induces autophagy-mediated cell death through AKT/mTOR signaling pathway in glioma cells. Bioscience Reports. 2019;39:BSR20192489.
79. Li MY, Zhang J, Lu X, Zhou D, Deng XF, Liu QX, et al. Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. Cancer Chemother Pharmacol. 2023.
80. Dou Q, Chen HN, Wang K, Yuan K, Lei Y, Li K, et al. Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Res. 2016;76(15):4457–69.
81. Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez M, et al. Ivermectin as an inhibitor of cancer stem-like cells. Mol. Med Rep. 2018;17(2):3397–403.
82. Nygren P, Larsson R. Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol. 2014;53(3):427–8.
83. Guerini AE, Triggiani L, Maddalo M, Bonu ML, Frassine F, Baiguini A, et al. Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers. 2019;11:1284.
84. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002;8(9):2963–9.
85. Laudisi F, Marônek M, Di Grazia A, Monteleone G, Stolfi C. Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System. Int J Mol Sci. 2020;21(14).
86. Walk-Vorderwulbecke V, Pearce K, Brooks T, Hubank M, Zwaan cM, Edwards AD, et al. Targeting acute myeloid leukemia by drug-induced c-MYB degradation. Leukemia. 2018;32:882–9.
87. Larsen AR, Bai RY, Chung JH, Borodovsky A, Rudin CM, Riggins GJ, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol. Cancer. Ther. 2015;14:3–13.
88. Williamson T, Bai RY, Staedtke V, Huso D, Riggins GJ. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget. 2016;7:68571–84.
89. Melotti A, Mas C, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014;6(10):1263–78.
90. Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207.
91. Lee DE, Kang HW, Kim SY, Kim MJ, Jeong JW, Hong WC, et al. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front Pharmacol. 2022;13:934746.
92. Joe NS, Wang Y, Oza HH, Godet I, Milki N, Riggins GJ, et al. Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells. Cancers (Basel). 2023;15(4).
93. Huang L, Zhao L, Zhang J, He F, Wang H, Liu Q, et al. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging (Albany NY). 2021;13(13):17407–27.
94. Hong J, Kwon KY, Jang DG, Kwon T, Yoon H, Park TJ. Mebendazole preferentially inhibits cilia formation and exerts anticancer activity by synergistically augmenting DNA damage. Biomed Pharmacother. 2024;174:116434.
95. Mansoori S, Fryknäs M, Alvfors C, Loskog A, Larsson R, Nygren P. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Sci Rep. 2021;11(1):8981.
96. Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K, Miltyk W. Celecoxib in Cancer Therapy and Prevention - Review. Curr Drug Targets. 2019;20(3):302–15.
97. Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, et al. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024;42(24):2853–9.
98. Ralph SJ, Nozuhur S, Moreno-Sanchez R, Rodriguez-Enriquez S, Pritchard R. NSAID celecoxib: a potent mitochondrial pro-oxidant cytotoxic agent sensitizing metastatic cancers and cancer stem cells to chemotherapy. Journal of Cancer Metastasis and Treatment. 2018;4:49.
99. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013;332(2):313–24.
100. Zhang J, Yang J. Allium Vegetables Intake and Risk of Breast Cancer: A Meta-Analysis. Iran J Public Health. 2022;51(4):746–57.
101. Yang Q, Li F, Jia G, Liu R. Aged black garlic extract inhibits the growth of estrogen receptor-positive breast cancer cells by downregulating MCL-1 expression through the ROS-JNK pathway. PLoS One. 2023;18(6):e0286454.
102. Wang X, Jiao F, Wang QW, Wang J, Yang K, Hu RR, et al. Aged black garlic extract induces inhibition of gastric cancer cell growth in vitro and in vivo. Mol Med Rep. 2012;5(1):66–72.
103. Tanaka S, Haruma K, Kunihiro M, Nagata S, Kitadai Y, Manabe N, et al. Effects of aged garlic extract (AGE) on colorectal adenomas: a double-blinded study. Hiroshima J Med Sci. 2004;53(3-4):39–45.
104. Tanaka S, Haruma K, Yoshihara M, Kajiyama G, Kira K, Amagase H, et al. Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. J Nutr. 2006;136(3 Suppl):821s–6s.
Sunshine is critical. difficult to get adequate levels with sunshine alone.
the best why to answer that question is to measure your vitamin D level.